Abstract
Excessive synapse loss is a core feature of schizophrenia and is linked to the complement component 4A gene (C4A). In two independent cohorts, we show that cerebrospinal fluid (CSF) C4A concentration is elevated in first-episode psychosis patients who develop schizophrenia and correlates with CSF measurements of synapse density. Using patient-derived cellular modeling, we find that disease-associated cytokines increase neuronal C4A expression and that IL-1β associates with C4A in patient-derived CSF.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We thank the patients who contributed to this study. Support from the Swedish National Infrastructure for Biological Mass Spectrometry (BioMS) is gratefully acknowledged. C.M.S is supported by grants from the Swedish Research Council, One Mind Foundation, Marianne and Marcus Wallenberg Foundation, and Erling-Persson Family Foundation. F.O received support from the Swedish Brain Foundation and the Swedish Society for Mecial Reseach. KB is supported by the Swedish Research Council (#2017-00915), the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-742881), Hjarnfonden, Sweden (#FO2017-0243), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the National Institute of Health (NIH), USA, (grant #1R01AG068398-01), and the Alzheimers Association 2021 Zenith Award (ZEN-21-848495). H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council, the European Research Council, and the Swedish Federal Government under the LUA/ALF agreement. NMI received financial support from the State Ministry of Baden-Wuerttemberg for Economic Affairs, Labour and Tourism. S.E. received financial support from the Swedish Research Council. The St. Goran study is supported by grants from the Swedish Research Council (M.L.), the Swedish Foundation for Strategic Research (M.L.), the Swedish Brain Foundation (M.L.), and the Swedish Federal Government under the LUA/ALF agreement (M.L.). KaSP is supported by grants from the Swedish Federal Government under the LUA/ALF agreement (C.M.S., S.E., and S.C.). All illustrations in Figures 1 and 2 were created with BioRender.com.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Regional Ethics Committee in Stockholm (Sweden) and the Institutional Review Board of Partners HealthCare (MA, USA). Informed consent was obtained from all included subjects.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data is available from the corresponding author upon reasonable request.
